020 - Question of the Month #5 — Supply Chain, Tech, Open Floor

We talked about single source risk back in episode seventeen, but I want to go a level deeper.

When you're actually evaluating a new supplier for a critical ingredient, what does quality sourcing actually look like in practice beyond checking a certificate of analysis? This is a great follow-up, and I wanna be specific here because this is exactly the kind of question where the difference between a superficial process and a real one shows up.

Quality sourcing starts before you ever request a sample.

The first step is documentation review.

Independent of anything the supplier sends you directly, check the FDA's Establishment Registration database if they manufacture in a facility subject to FDA oversight.

Check the FDA's Warning Letter database and Import Alert lists.

For an EU-based supplier, check the EU's database, um, for all of those warnings, and this tells you in about twenty minutes whether the supplier has a recent history of significant quality system failures that they may not volunteer in a sales conversation.

Second, request their certificate of analysis format and their specification sheet before you request a sample and compare their specification against your actual requirement.

A surprising number of supply relationships go wrong because the buyer assumed the supplier's standard specification matched what the buyer actually needed, when in fact, the supplier's specification was written for a different application with looser tolerances.

If their standard C of A doesn't test for an attribute that's critical to your formula, a specific impurity, a particle size range, or even a microbial limit, you need to negotiate custom testing or plan to test it yourself at incoming inspection.

Third, and this is the step that most commonly gets skipped.

Test the actual material against your full specification before you qualify the supplier, not after.

Request a sample lot, run it through your own analytical testing, and confirm that it performs in your formula the way that your existing material does.

A certificate of analysis tells you what the supplier's lab found.

It doesn't tell you how the material behaves in your specific application at your specific concentration with your specific processing conditions.

Fourth, for any ingredient that's genuinely critical to your product's performance, safety, or regulatory compliance, do not stop at the documentation.

Get eyes on the operation, either yours or use a qualified, um, third party, like consulting firm that I run, and do a remote audit at a minimum that includes photos or video documentation of the manufacturing environment, storage condition, and basic GMP practices.

For pharmaceutical API suppliers specifically, this is not optional.

You need direct or delegated audit access as part of your regulatory obligation.

And fifth, put a quality agreement in place before you place a commercial order, not after the relationship is already running Specification, change notification requirements, nonconformance handling, the audit rights, all of it in writing.

If a supplier resists formalizing that agreement, that reluctance that itself is information about how they'll behave when something eventually goes wrong.

Quality sourcing is slower than price-based sourcing.

It should be.

The cost of doing it properly is measured in weeks.

The cost of skipping it is measured in recalls, reformulations, and the worst case, regulatory action.